Finance News Network

Finance News Network Finance News Network is Australia’s largest provider of online business and finance video news. So keep your finger on the pulse and stay abreast of markets.

FNN connects investors with investment opportunities, with the latest ASX news, CEO and fund manager interviews and Investor Events. FNN’s Investor Events give CEOs a platform to present their investment case, network with stockbrokers and meet shareholders. Our news is also broadcast across some of Australia’s most prominent investment platforms. Tune in to FNN.

Cybersecurity, Copper, Genomics & PGM - 4 ASX Companies, 1 Power-Packed Webinar!Join us 19 Jun, 12:30pm AEST to hear fro...
13/06/2025

Cybersecurity, Copper, Genomics & PGM - 4 ASX Companies, 1 Power-Packed Webinar!

Join us 19 Jun, 12:30pm AEST to hear from archTIS, Copper Search Limited, EZZ Life Science Holdings ASX:EZZ & Southern Palladium Limited.

Free to attend - Register now: https://us02web.zoom.us/webinar/register/WN_QweRlKwbS6ui6tiQ2eN0xg

ASX:AR9 ASX:SPD ASX:CUS ASX:EZZ

US stocks struggled last week as concerns over inflation and US president-elect Donald Trump’s tariff plans weighed on s...
15/12/2024

US stocks struggled last week as concerns over inflation and US president-elect Donald Trump’s tariff plans weighed on sentiment.

16 Dec 2024 - US stocks struggled last week as concerns over inflation and US president-elect Donald Trump’s tariff plans weighed on sentiment.

Shaw and Partners Chief Investment Officer Martin Crabbe outlines a four-part investment strategy, focusing on growth, f...
13/12/2024

Shaw and Partners Chief Investment Officer Martin Crabbe outlines a four-part investment strategy, focusing on growth, financial conditions, central bank policy and valuation. He notes that valuations remain high. He advises investors to adopt an active strategy, selecting individual growth-oriented stocks instead of relying on index funds.

13 Dec 2024 - Shaw and Partners Chief Investment Officer Martin Crabbe outlines a four-part investment strategy, focusing on growth, financial conditions, central bank policy and valuation. He notes that valuations remain high. He advises investors to adopt an active strategy, selecting individual g...

Dr Leearne Hinch - CEO - INOVIQ Limited (ASX:IIQ) is developing and commercialising a portfolio of diagnostic and exosom...
13/12/2024

Dr Leearne Hinch - CEO - INOVIQ Limited (ASX:IIQ) is developing and commercialising a portfolio of diagnostic and exosome-based products for the earlier detection, diagnosis, prognosis and monitoring of cancer and other diseases.

13 Dec 2024 - Dr Leearne Hinch - CEO - INOVIQ Limited (ASX:IIQ) is developing and commercialising a portfolio of diagnostic and exosome-based products for the earlier detection, diagnosis, prognosis and monitoring of cancer and other diseases.

Dougal Ferguson - CEO - TMK Energy Limited’s (ASX:TMK) flagship project, the Gurvantes ###V Project, is a comprehensive ...
13/12/2024

Dougal Ferguson - CEO - TMK Energy Limited’s (ASX:TMK) flagship project, the Gurvantes ###V Project, is a comprehensive Coal Seam Gas exploration initiative covering an expansive area of approximately 8,400 km2 in the South Gobi basin of Mongolia.

29 Nov 2024 - Dougal Ferguson - CEO - TMK Energy Limited’s (ASX:TMK) flagship project, the Gurvantes ###V Project, is a comprehensive Coal Seam Gas exploration initiative covering an expansive area of approximately 8,400 km2 in the South Gobi basin of Mongolia.

Dr David Stamler - CEO - Alterity Therapeutics Limited (ASX:ATH) is developing first-in-class therapies to treat neurode...
13/12/2024

Dr David Stamler - CEO - Alterity Therapeutics Limited (ASX:ATH) is developing first-in-class therapies to treat neurodegenerative disease. The company's lead drug candidate, ATH434, has demonstrated efficacy in several animal models of Parkinsonian disorders and is being evaluated in clinical trials.

29 Nov 2024 - Dr David Stamler - CEO - Alterity Therapeutics Limited (ASX:ATH) is developing first-in-class therapies to treat neurodegenerative disease. The company's lead drug candidate, ATH434, has demonstrated efficacy in several animal models of Parkinsonian disorders and is being evaluated in....

Address

Level 7, 1 Castlereagh Street
The Rocks, NSW
2000

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Alerts

Be the first to know and let us send you an email when Finance News Network posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Finance News Network:

Share